Literature DB >> 15736349

Occurrence of Burkholderia cepacia in the hospital environment.

J E Moore1, B McIlhatton, J Buchanan, D Gilpin, A Shaw, V Hall, P G Murphy, J S Elborn.   

Abstract

AIM: To determine the prevalence of Burkholderia cepacia from the environment in a regional adult cystic fibrosis (CF) care centre.
METHODS: Two hundred and eighty-five environmental samples were taken from inpatient and outpatient environments within the CF centre. Following a non-selective enrichment step, broths were plated onto a selective medium and B. cepacia isolates were confirmed by phenotypic tests and also genotypically by species specific 16S rRNA PCR.
RESULTS: B. cepacia was not detected from commonly shared items of equipment, staff hands, staff uniforms or toilets. In addition, the organism was not detected in toilet bowls, even in the B. cepacia unit. With regard to positive environments for B. cepacia, 4/10 (40%) of the outside surfaces and inner rims of patients' plastic disposable sputum collection containers and 4/17 (23.5%) of air from patients' rooms, following physiotherapy, were positive.
CONCLUSIONS: All positive samples originated in the B. cepacia segregation area of the inpatient wards and B. cepacia was not detected in the non-cepacia area of the CF centre. Consequently, these two positive sites should therefore be treated as high risk, where organisms may be potentially transmitted from environment to patient. As there is now evidence to suggest differences in the virulence and hence clinical outcome of certain of the genomovars of this organism, this study may be important in highlighting the areas that patients who are B. cepacia positive should avoid, to minimise the risk of transmission and acquisition of this organism within the CF cepacia population. These results indicate that effective infection control procedures are required in patients' rooms following physiotherapy, for prevention of B. cepacia transmission and to avoid the transmission of different genomovar types within CF patients, who are already colonised with this pathogen.

Entities:  

Mesh:

Year:  2002        PMID: 15736349     DOI: 10.1007/bf03170498

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  9 in total

1.  Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis.

Authors:  A De Soyza; A McDowell; L Archer; J H Dark; S J Elborn; E Mahenthiralingam; K Gould; P A Corris
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

2.  Burkholderia cepacia from a sink drain.

Authors:  J E Moore; I Thompson; M Crowe; J Xu; A Shaw; B C Millar; A O B Redmond; A J M Reid; C Clarke; J S Elborn
Journal:  J Hosp Infect       Date:  2002-03       Impact factor: 3.926

3.  PCR-based detection and identification of Burkholderia cepacia complex pathogens in sputum from cystic fibrosis patients.

Authors:  A McDowell; E Mahenthiralingam; J E Moore; K E Dunbar; A K Webb; M E Dodd; S L Martin; B C Millar; C J Scott; M Crowe; J S Elborn
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

4.  Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward.

Authors:  G Döring; S Jansen; H Noll; H Grupp; F Frank; K Botzenhart; K Magdorf; U Wahn
Journal:  Pediatr Pulmonol       Date:  1996-02

5.  Identification of Burkholderia spp. in the clinical microbiology laboratory: comparison of conventional and molecular methods.

Authors:  C van Pelt; C M Verduin; W H Goessens; M C Vos; B Tümmler; C Segonds; F Reubsaet; H Verbrugh; A van Belkum
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

6.  Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov.

Authors:  P Vandamme; B Holmes; M Vancanneyt; T Coenye; B Hoste; R Coopman; H Revets; S Lauwers; M Gillis; K Kersters; J R Govan
Journal:  Int J Syst Bacteriol       Date:  1997-10

7.  Detection of Pseudomonas (Burkholderia) cepacia using PCR.

Authors:  P W Campbell; J A Phillips; G J Heidecker; M R Krishnamani; R Zahorchak; T L Stull
Journal:  Pediatr Pulmonol       Date:  1995-07

8.  Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov.

Authors:  E Yabuuchi; Y Kosako; H Oyaizu; I Yano; H Hotta; Y Hashimoto; T Ezaki; M Arakawa
Journal:  Microbiol Immunol       Date:  1992       Impact factor: 1.955

9.  Cystic fibrosis: infection.

Authors:  N Høiby
Journal:  Schweiz Med Wochenschr       Date:  1991-01-26
  9 in total
  1 in total

1.  Physiotherapy for cystic fibrosis in Australia and New Zealand: A clinical practice guideline.

Authors:  Brenda M Button; Christine Wilson; Ruth Dentice; Narelle S Cox; Anna Middleton; Esta Tannenbaum; Jennifer Bishop; Robyn Cobb; Kate Burton; Michelle Wood; Fiona Moran; Ryan Black; Summar Bowen; Rosemary Day; Julie Depiazzi; Katherine Doiron; Michael Doumit; Tiffany Dwyer; Alison Elliot; Louise Fuller; Kathleen Hall; Matthew Hutchins; Melinda Kerr; Annemarie L Lee; Christina Mans; Lauren O'Connor; Ranjana Steward; Angela Potter; Tshepo Rasekaba; Rebecca Scoones; Ben Tarrant; Nathan Ward; Samantha West; Dianne White; Lisa Wilson; Jamie Wood; Anne E Holland
Journal:  Respirology       Date:  2016-04-18       Impact factor: 6.424

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.